# ALXO — Alx Oncology Holdings Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** ALXO  
**Sources:** 16  
**Published:** 2026-10-04  
**Canonical:** https://app.k3vl4r.com/research/deep-research-alxo-alx-oncology-holdings-inc-catalysts-narrative-risks-5997

---

# ALX Oncology Holdings Inc. (ALXO) — Research Summary

*As of 2026-10-04. The following is a synthesis of provided sources for informational purposes and does not constitute investment advice.*

## Company & Current Market Snapshot
ALX Oncology Holdings Inc. (Nasdaq: ALXO) is a U.S.-listed, clinical-stage immuno-oncology company [background, 12, 13]. Its lead candidate is evorpacept (a CD47-blocking biologic) and its second candidate is ALX2004 (an EGFR-targeted antibody-drug conjugate) [[5]](https://markets.businessinsider.com/news/stocks/alx-oncology-to-present-at-upcoming-investor-conferences-in-september-1036515132)[[12]](https://ir.alxoncology.com/)[[13]](https://alxoncology.com/pipeline/).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-alxo-alx-oncology-holdings-inc-catalysts-narrative-risks-5997 (free to sign up)._
